<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/brokerages-anticipate-integra-lifesciences-holdings-corp-nasdaqiart-to-post-0-67-earnings-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T18:50:41+00:00"/>
    <meta property="og:title" content="Brokerages Anticipate Integra Lifesciences Holdings Corp (NASDAQ:IART) to Post $0.67 Earnings Per Share"/>
    <meta property="og:description" content="Wall Street analysts forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings per share (EPS) of $0.67 for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Integra Lifesciences’ earnings, with estimates ranging from $0.67 to $0.68. Integra Lifesciences posted earnings per share of $0.65 in the same quarter last […]"/>
  </head>
  <body>
    <article>
      <h1>Brokerages Anticipate Integra Lifesciences Holdings Corp (NASDAQ:IART) to Post $0.67 Earnings Per Share</h1>
      <address><time datetime="2019-11-24T18:50:41+00:00">24 Nov 2019, 18:50</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/integra-lifesciences-holdings-corp-logo.png"/>
      </figure>
      <p>Wall Street analysts forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings per share (EPS) of $0.67 for the current fiscal quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a>. Five analysts have made estimates for Integra Lifesciences’ earnings, with estimates ranging from $0.67 to $0.68. Integra Lifesciences posted earnings per share of $0.65 in the same quarter last year, which indicates a positive year-over-year growth rate of 3.1%. The business is expected to report its next earnings results on Thursday, February 20th.</p>
      <p>On average, analysts expect that Integra Lifesciences will report full year earnings of $2.74 per share for the current fiscal year, with EPS estimates ranging from $2.73 to $2.75. For the next financial year, analysts expect that the company will report earnings of $2.99 per share, with EPS estimates ranging from $2.93 to $3.02. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Integra Lifesciences.</p>
      <p>Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Thursday, October 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The firm had revenue of $379.10 million for the quarter, compared to analysts’ expectations of $376.85 million. Integra Lifesciences had a net margin of 3.99% and a return on equity of 16.83%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business earned $0.59 earnings per share.</p>
      <p>IART has been the subject of several recent analyst reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IART">ValuEngine</a> lowered Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 14th. TheStreet lowered Integra Lifesciences from an “a-” rating to a “c+” rating in a research report on Thursday, October 24th. Wells Fargo &amp; Co set a $62.00 price target on Integra Lifesciences and gave the stock a “hold” rating in a research report on Friday, October 25th. Oppenheimer set a $68.00 price target on Integra Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, BidaskClub raised Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $61.82.</p>
      <p>In other Integra Lifesciences news, CEO Peter J. Arduini sold 250,000 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $60.55, for a total value of $15,137,500.00. Following the completion of the transaction, the chief executive officer now owns 433,017 shares of the company’s stock, valued at approximately $26,219,179.35. The sale was disclosed in a legal filing with the SEC, which is available through <a href="https://www.sec.gov/Archives/edgar/data/917520/000120919119049009/xslF345X03/doc4.xml">this link</a>. Also, VP John Mooradian sold 9,249 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.53, for a total value of $578,339.97. Following the completion of the transaction, the vice president now directly owns 18,706 shares of the company’s stock, valued at approximately $1,169,686.18. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/917520/000120919119049474/xslF345X03/doc4.xml">here</a>. In the last three months, insiders sold 779,249 shares of company stock valued at $47,420,240. 4.50% of the stock is owned by insiders.</p>
      <p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in IART. Janus Henderson Group PLC increased its position in shares of Integra Lifesciences by 13.1% during the 2nd quarter. Janus Henderson Group PLC now owns 3,248,870 shares of the life sciences company’s stock valued at $181,449,000 after purchasing an additional 375,546 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Integra Lifesciences by 198.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 399,294 shares of the life sciences company’s stock valued at $22,301,000 after purchasing an additional 265,335 shares during the last quarter. Marshall Wace LLP increased its position in shares of Integra Lifesciences by 110.4% during the 2nd quarter. Marshall Wace LLP now owns 402,316 shares of the life sciences company’s stock valued at $22,470,000 after purchasing an additional 211,100 shares during the last quarter. First Trust Advisors LP increased its position in shares of Integra Lifesciences by 922.1% during the 2nd quarter. First Trust Advisors LP now owns 211,299 shares of the life sciences company’s stock valued at $11,801,000 after purchasing an additional 190,626 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Integra Lifesciences during the 2nd quarter valued at about $9,711,000. 80.61% of the stock is owned by hedge funds and other institutional investors.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/IART/earnings/">NASDAQ:IART</a> traded up $0.22 during trading hours on Friday, hitting $59.19. The company had a trading volume of 226,800 shares, compared to its average volume of 375,765. The stock has a 50-day moving average price of $59.20 and a 200 day moving average price of $56.93. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.92 and a quick ratio of 1.92. The company has a market capitalization of $5.06 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 1.74 and a beta of 1.09. Integra Lifesciences has a 52 week low of $42.14 and a 52 week high of $65.09.</p>
      <p>
        <b>About Integra Lifesciences</b>
      </p>
      <p>Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/difference-between-common-shares-and-convertible-shares/">Why do companies issue convertible shares?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=IART">Get a free copy of the Zacks research report on Integra Lifesciences (IART)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=IART"/>
      </figure>
    </article>
  </body>
</html>